Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
3Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Amylyx Pharmaceuticals, Inc. (AMLX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
8Total relationships
1Distinct source URLs
5High confidence
0.770Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Amylyx Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CMOS
CMOS
80%
expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials
CROS
CROS
80%
expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials
Amylyx Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
s. The decrease in other expenses is primarily due to lower facilities and IT-related expenses. Liquidity and Capital Resources Sources of Liquidity As of March 31, 2026, we had cash, cash equivalent…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ious or future acquisitions or business combinations will, in fact, produce any benefits. For example, we may not receive the anticipated benefits of the acquisition of avexitide for some time. Acqui…
EIGER-BIOPHARMACEUTICALS-INC
EIGER-BIOPHARMACEUTICALS-INC
62%
ts with any financial institution that has experienced such events, if any financial institution with which we have a relationship were to be placed into receivership, we may be unable to access such…
Amylyx Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AMLX-DEBT-7729
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
AMLX-DEBT
Debt stack $5.6M
90%
Market cache reports total debt of $5.6M.
Amylyx Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Amylyx Pharmaceuticals, Inc..
Amylyx Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
AMLX-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 174 tracked holders.
Amylyx Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
